Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

ClinicalTrials.gov ID: NCT02865434

Public ClinicalTrials.gov record NCT02865434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls

Study identification

NCT ID
NCT02865434
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Navidea Biopharmaceuticals
Industry
Enrollment
39 participants

Conditions and interventions

Interventions

  • Tc99m-tilmanocept Drug
  • SPECT Imaging (60 Minutes post-injection) Procedure
  • SPECT Imaging (180 Minutes post-injection) Procedure
  • Whole body planar SPECT imaging (15 Minutes post-injection) Procedure
  • Whole body planar SPECT imaging (60 Minutes post-injection) Procedure
  • Whole body planar SPECT imaging (180 Minutes post-injection) Procedure
  • Whole body planar SPECT imaging (18-20 Hours post-injection) Procedure
  • Blood Collection for PK Testing (15 Mins Before Injection) Procedure
  • Blood Collection for PK Testing (after injection) Procedure
  • Blood Collection for PK Testing (15 minutes post injection) Procedure
  • Blood Collection for PK Testing (60 minutes post injection) Procedure
  • Blood Collection for PK Testing (180 minutes post injection) Procedure
  • Blood Collection for PK Testing (18-20 hours post injection) Procedure
  • Planar Image with both Hands in Field of View Procedure

Drug · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2016
Primary completion
May 31, 2018
Completion
May 31, 2018
Last update posted
Aug 11, 2021

2017 – 2018

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Kettering Medical Center Kettering Ohio 45429 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02865434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2021 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02865434 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →